Stockscreener 앱 받기
0.61%
Pfizer Inc 주식(PFE)의 최신 뉴스
Weight Loss Drugs Market Set to Reach USD 50.26 Billion by 2032, Driven by Prescription Drug Adoption and Breakthrough Formulations – SNS Insider - GlobeNewswire Inc.
Pfizer's (PFE) Crizotinib Shows Promise in Uveal Melanoma Trial - GuruFocus
Pfizer (PFE): Promising Data from VERITAC-2 Trial on Breast Canc - GuruFocus
PFIZER INC : JP Morgan sticks Neutral - MarketScreener
What analyst consensus implies for Pfizer Inc. (PFE) stockJuly 2025 PreEarnings & Technical Pattern Based Signals - nchmf.gov.vn
Pfizer: XTANDI Plus Leuprolide Cuts Death Risk 40% In High-Risk NmHSPC Phase 3 Study - Nasdaq
Pfizer (PFE) Reports Positive PADCEV Trial Results at ESMO 2025 - GuruFocus
Pfizer Stock Surges 15% on Trump’s Pricing Pact & $7.3B Obesity Deal – Can the Rally Last? - ts2.tech
XTANDI® Plus Leuprolide Reduced Risk of Death by 40% vs Leuprolide Alone in Men with a Type of Advanced Prostate Cancer - Pfizer
Pfizer Co & Astellas announce final overall survival results from Phase 3 Embark study for Xtandi in combination with Leuprolide - MarketScreener
40.3% lower risk of death — XTANDI + leuprolide raises 8‑yr OS to 78.9% in nmHSPC (Pfizer) - Stock Titan
Pfizer says Braftovi + Mektovi shows sustained long-term survival in patients with advanced lung cancer - MarketScreener
Pfizer’s BRAFTOVI® + MEKTOVI® Shows Sustained Long-Term Survival in Patients with Advanced Lung Cancer - Business Wire
Pfizer Stock Forecast – PFE Rises to $24.51 as Metsera Buyout and Seagen Synergies Drive 2025 Growth - TradingNEWS
What insider trading reveals about Pfizer Inc. stockWeekly Investment Recap & Reliable Breakout Stock Forecasts - nchmf.gov.vn
How Positive Phase 3 Cancer Drug Results at Pfizer (PFE) Have Changed Its Investment Story - simplywall.st
PADCEV™ Plus KEYTRUDA™, Given Before and After Surgery, Cuts the Risk of Recurrence, Progression or Death by 60% and the Risk of Death by 50% for Certain Patients with Bladder Cancer - Pfizer
Will Pfizer Inc. stock benefit from sector rotationMarket Activity Recap & Weekly Watchlist for Hot Stocks - nchmf.gov.vn
Astellas Pharma Inc. and Pfizer Inc. Announces Positive Results from the Pivotal Phase 3 EV-303 Clinical Trial (Also Known as Keynote-905) for PADCEV - MarketScreener
Will Pfizer Inc. (PFE) stock deliver compounding returns2025 Key Highlights & Reliable Price Action Trade Plans - nchmf.gov.vn
Pfizer and Astellas announce positive results from phase 3ev-303 clinical trial for Padcev in combination with Keytruda - MarketScreener
Why Pfizer Inc. stock is considered a top pick2025 Top Decliners & Free Growth Oriented Trading Recommendations - nchmf.gov.vn
Astellas-Pfizer's combination therapy halves risk of death in bladder cancer patients - MarketScreener
Will Pfizer Inc. stock attract ESG investorsJuly 2025 Sector Moves & Smart Money Movement Tracker - nchmf.gov.vn
Did Pfizer Overpay For Yet Another Acquisition? (NYSE:PFE) - Seeking Alpha
Pfizer: World-Leading Drug Pipeline Sets Stage For Major Long-Term Potential (NYSE:PFE) - Seeking Alpha
How Pfizer Inc. (Common Stock) (PFEB) stock behaves under inflation pressure2025 Volatility Report & Low Risk Profit Maximizing Plans - nchmf.gov.vn
Will Pfizer Inc. stock split again soonJuly 2025 PreEarnings & AI Enhanced Execution Alerts - nchmf.gov.vn
Is Pfizer Inc. stock a buy on dipsJuly 2025 Sector Moves & AI Driven Price Forecasts - nchmf.gov.vn
Can Pfizer Inc. (PFE) stock deliver strong annual returnsQuarterly Trade Review & Consistent Income Trade Recommendations - nchmf.gov.vn
Is Pfizer Inc. stock a good choice for value investors2025 Year in Review & Technical Pattern Based Signals - nchmf.gov.vn
RSI Check: Is Pfizer Inc. stock positioned well for digital economy2025 Market Trends & Step-by-Step Trade Execution Guides - nchmf.gov.vn
Can Pfizer Inc. (PFE) stock retain market dominance2025 Key Lessons & Long-Term Growth Stock Strategies - nchmf.gov.vn
Why Pfizer Inc. stock attracts high net worth investorsPrice Action & Reliable Breakout Forecasts - nchmf.gov.vn
Risk Off: Is Pfizer Inc. stock a good choice for value investors2025 Key Highlights & Entry Point Confirmation Signals - nchmf.gov.vn
Metsera, Inc. Announces Special Meeting for Merger Vote with Pfizer - TipRanks
Popular birth control is linked to brain tumors in new study — as over 1,000 women sue Pfizer over health risks - New York Post
Why Pfizer Inc. (Common Stock) (PFEB) stock is upgraded to buyWeekly Risk Report & Safe Capital Growth Trade Ideas - nchmf.gov.vn
Novo Vs. Lilly Vs. Pfizer: Who Wins If Trump Slashes The Price Of Weight Loss Drugs? - Benzinga
What’s Behind The Slump In Pfizer Stock? - Forbes
RFPs: Pfizer Clostridioides difficile (C. difficile) Research Collaboration Program - fundsforNGOs
Pfizer Faces Growing Legal Storm Over Depo-Provera as Brain Tumor Lawsuits Surge - The Legal Examiner
Day 9 of Loss Streak for Pfizer Stock with -11% Return (vs. -3.8% YTD) [10/16/2025] - Trefis
Pfizer chairman/CEO to be honored by Israel’s largest university - New Jersey Jewish News
QSM Asset Management Buys $6.8 Million of Pfizer Stock as Pharma Giant Lags Market - sharewise.com
ASSET PLANNING Exits Full Stake in Pfizer Worth $2.7 Million - The Globe and Mail
Pfizer CEO touts Trump drug-price deal amid vaccine doubts - Crain's New York Business
Pfizer Goes All In On TrumpRx. Is Pfizer Stock Now A Buy? - Investor's Business Daily
Institutional Investors May Adopt Severe Steps After Pfizer Inc.'s (NYSE:PFE) Latest 5.0% Drop Adds to a Year Losses - 富途牛牛
Pfizer Strikes $70B Deal with Trump--But Warns China Is Racing Ahead in Biotech War - Yahoo Finance
Acquired Hemophilia A Pipeline 2025: Comprehensive Clinical Trials and Therapies Analysis with Key MOA and ROA Insights by DelveInsight | Novo Nordisk, Sanofi, Pfizer, Belief BioMed, Centessa Pharma - Barchart.com
Pfizer’s Q3 2025 Earnings: What to Expect - MSN
Pfizer: Don't Forget About Value During AI Frenzy (NYSE:PFE) - Seeking Alpha
Day 8 of Loss Streak for Pfizer Stock with -11% Return (vs. -3.1% YTD) [10/15/2025] - Trefis
Press Release: Congressman Bill Huizenga Applauds Trump Administration and Pfizer's Agreement to Lower Drug Prices and Invest in U.S. - Quiver Quantitative
Pfizer CEO Says Vaccine Approvals Are Harder to Get Right Now - Bloomberg.com
CEOs of Wells Fargo and Pfizer caution the U.S. could lose its edge to China without innovation - CNBC
AstraZeneca joins Pfizer in most-favored nation pricing program - TechTarget
Advanced Ovarian Cancer Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Pfizer, Daiichi Sankyo, Astellas Pharma, Jiangsu HengRui, Boehringer - Barchart.com
GSK Fights Pfizer's Bid To Nix COVID-19 Vaccine Patents - Law360
Pfizer CEO Reportedly Says US Pharmaceutical Industry Should Collaborate With Chinese Counterparts - MarketScreener
0.41%
0.32%
자본화:
|
볼륨(24시간):